KENILWORTH, N.J., Jan. 12 /PRNewswire/ -- Schering-Plough Corporation today announced several changes within its research and development operations.
Effective immediately, Thomas P. Koestler, Ph.D., is appointed executive vice president, global development, Schering-Plough Research Institute (SPRI). Also effective immediately, James S. MacDonald, Ph.D., is appointed executive vice president, preclinical development, SPRI. Both report to Cecil B. Pickett, Ph.D., senior vice president and president, SPRI and continue as members of the Operations Management Team (OMT).
"These changes are designed to further strengthen Schering-Plough Research Institute's development operations worldwide, as we transform the company into a successful global competitor beginning with our anticipated turnaround this year," said Fred Hassan, chairman and chief executive officer, Schering-Plough Corporation.
In his new role, Dr. Koestler will set strategic direction and implementation plans for the new development organization, which will include worldwide clinical development, pharmaceutical sciences, global regulatory affairs and global project management. Before joining Schering-Plough in 2003 as executive vice president, global regulatory affairs and global project management, Koestler was senior vice president, global regulatory affairs, Pharmacia Corporation. He also held positions of increasing responsibility at Novartis Pharmaceutical Corporation and the R.W. Johnson Pharmaceutical Research Institute, Ortho McNeil Pharmaceutical Corporation.
In his new role, Dr. MacDonald will continue to have direct responsibility for the drug safety and metabolism group as well as the newly created SPRI computer validation group. He will be responsible for assuring a steady flow of new compounds for the development pipeline by establishing effective working relationships with the appropriate groups in discovery, pharmaceutical sciences and clinical research. MacDonald joined Schering-Plough Corporation in 1994 as senior vice president, drug, safety and metabolism. Prior to this, he held positions of increasing responsibility at Merck and Co., Inc.
The company also announced that the research and development function supporting Schering-Plough K.K. (SPKK), the global pharmaceutical business in Japan, will report to Peder K. Jensen, M.D., executive vice president, global clinical development, SPRI, through Masao Torii, president, SPKK. Dr. Jensen is also a member of the OMT.
Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its more than 30,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com/.